Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Lilly and AbCheck pursue antibody targets
November 2010
SHARING OPTIONS:

PLZEN, Czech Republic—AbCheck SRO has signed a discovery deal with Eli Lilly & Co. under which AbCheck will use its three antibody discovery libraries to deliver high-affinity, fully human antibodies against an undisclosed number of Lilly targets. The three distinct human antibody libraries comprise a total of about 10 billion sequentially and structurally diverse antibodies. Lilly, which has full rights to any antibodies selected, will pay AbCheck discovery fees and development milestone payments. Other financial and deal terms are not disclosed.
 
According to AbCheck, its libraries are designed as universal tools for the isolation of antibodies against all possible targets and are different from immunized libraries, which are restricted to only a minor fraction of therapeutically interesting target antigens.
 
"This discovery deal with Lilly is an important validation of our antibody discovery and business approach," says Dr. Volker Lang, managing director of AbCheck. "Signing our first deal with such a significant company so soon after setting up AbCheck has certainly given us a tremendous boost of confidence that AbCheck is following a successful business strategy."
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.